New treatment to reduce bleeding in patients with low platelet counts
Official title: SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia
Funded at Haima Therapeutics, LLC · NIH-11285688 · Data updated 2026-11-12
This study is testing a new type of treatment that uses tiny particles to help people with low platelet counts, like those undergoing chemotherapy or dealing with autoimmune disorders, by providing a better way to prevent excessive bleeding.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Haima Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | March 27, 2025 |
| Project end | May 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $50,000 |
| NIH project number | 3R44HL145948-03S2 |
| Project ID | NIH-11285688 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with thrombocytopenia, particularly those with autoimmune conditions or those undergoing chemotherapy.
✕Less likely to help
Patients with normal platelet counts or those whose bleeding issues are not related to thrombocytopenia may not benefit from this research.
What this research studies
This research focuses on developing a novel intravenous nanotechnology designed to help patients with thrombocytopenia, a condition characterized by low platelet counts that can lead to excessive bleeding. The approach aims to create a synthetic platelet substitute that can effectively mitigate bleeding risks, especially in patients undergoing chemotherapy or suffering from autoimmune disorders. By addressing the limitations of current platelet transfusions, this research seeks to provide a more reliable and longer-lasting solution for managing bleeding complications in these patients.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of bleeding complications for patients with low platelet counts, improving their quality of life and treatment outcomes.
How similar studies have gone: While the approach of using nanotechnology for hemostatic purposes is innovative, similar strategies have shown promise in other areas of bleeding management, indicating potential for success.
Where this research is happening
-
Haima Therapeutics, LLC
Cleveland, United States Active
Researchers
- Principal investigator: Bruckman, Michael Arthur — Haima Therapeutics, LLC
- Study coordinator: Bruckman, Michael Arthur
Related research
Other NIH-funded projects on the same topics.
-
New ideas to understand, diagnose, and treat heparin-induced thrombocytopenia
A Mayo Clinic led study will look at the different kinds of HIT antibodies to improve diagnosis and treatment for people with HIT.
-
Second-generation BLVRB inhibitors to help chemotherapy patients with low platelets
A new drug candidate is being developed to raise platelet counts in patients whose cancer treatment lowers them, reducing bleeding risk.
-
Direct measurement of RhD sensitization after early-pregnancy bleeding
This study tests how often Rh immunoglobulin given after bleeding in early pregnancy prevents RhD sensitization in pregnant people.
-
EpiMAX: a new injectable gel that stops GI bleeding quickly and for days
A new injectable hydrogel with epinephrine-loaded microparticles is designed to plug GI bleeds and provide immediate and lasting hemostasis for about 72 hours.
-
Dynamic risk tools to prevent blood clots and bleeding in cancer patients
A new AI-based approach will predict who among people with cancer starting treatment is at higher risk for blood clots or dangerous bleeding, helping doctors tailor preventive care.
-
Bleeding and Platelet Problems in Ehlers-Danlos Syndrome
This NIH grant looks at why people with Ehlers-Danlos syndrome bleed more and how platelet function is involved, with goals that could lead to better care during surgery or emergencies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.